Biopharma PEG Scientific Inc.

Biopharma PEG, a leading manufacturer of high-quality polyethylene glycol (PEG) derivatives, today announced that its mPEG-pAld (20K) product has successfully achieved DMF (Drug Master File) II registration with the U.S.

In the spirit of Thanksgiving, Biopharma PEG Scientific Inc. would like to express its sincere gratitude to our esteemed customers and partners for their trust and support.

Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications.

Biopharma PEG, a key provider of premium polyethylene glycol (PEG) derivatives, is thrilled to announce a substantial expansion of its large-scale Good Manufacturing Practice (GMP) production capabilities.

Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields.

Biopharma PEG, a top supplier of PEG derivatives, is excited to introduce its new line of monodispersed PEGs. These specially sized polymers are designed to improve the stability and delivery of proteins and peptides in drugs.

Biopharma PEG, a leading provider of advanced polyethylene glycol (PEG) derivatives, is excited to announce its participation in the BIO International Convention 2024, scheduled to take place from June 3-6, 2024, at the San Diego Convention Center.

Biopharma PEG Scientific Inc., a pioneering biotechnology company based in Watertown, Massachusetts, is set to make a significant impact at the upcoming PEGS Boston Summit and TIDES USA 2024 conferences.

Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which can be used in drug development, click chemistry, ADCs (Antibody Drug Conjugates), PROTACs (Proteolysis Targeting...

Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development.